Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis-Reference-Cited by-同舟云学术

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis

Published:2018-07-04 Issue:3 Volume:101 Page:305-317
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Shahnaz Syed Abd Kadir Sharifah¹²,Christopeit Maximilian¹,Wulf Gerald³,Wagner Eva⁴,Bornhauser Martin⁵,Schroeder Thomas⁶,Crysandt Martina⁷,Mayer Karin⁸,Jonas Julia⁸,Stelljes Matthias⁹,Badbaran Anita¹,Ayuketang Ayuk Francis¹,Triviai Ioanna¹,Wolf Dominik⁸,Wolschke Christine¹,Kröger Nicolaus¹^ORCID

Affiliation:

1. Department of Stem Cell Transplantation; University Medical Center Hamburg-Eppendorf; Hamburg Germany

2. Department of Haematology; Ampang Hospital; Selangor Malaysia

3. Department of Hematology/Oncology; University Hospital Göttingen; Göttingen Germany

4. Department for Hematology and Oncology; University Hospital Mainz; Mainz Germany

5. Department for Hematology and Oncology; University Hospital Dresden; Dresden Germany

6. Department for Hematology, Oncology and Clinical Immunology; University Hospital Duesseldorf; Düsseldorf Germany

7. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation; Faculty of Medicine; RWTH Aachen University; Aachen Germany

8. Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology; University Clinic Bonn (UKB); Bonn Germany

9. Department of Medicine A, Hematology and Oncology; University of Muenster; Muenster Germany

Funder

Novartis

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13099/fullpdf

Reference44 articles.

1. Myelofibrosis with myeloid metaplasia;Tefferi;N Engl J Med,2000

2. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med,2005

3. Pathogenesis of myeloproliferative neoplasms;Skoda;Exp Hematol,2015

4. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

5. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial;Mesa;J Clin Oncol,2013

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelofibrosis and allogeneic transplantation: critical points and challenges;Frontiers in Oncology;2024-06-20

2. Are transplant indications changing for myelofibrosis?;Hematology;2023-12-08

3. How I treat transplant-eligible patients with myelofibrosis;Blood;2023-11-16

4. Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis;Blood Reviews;2023-07

5. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis;Bone Marrow Transplantation;2023-03-31